Automated Stress Detection and Restoration in Office Workers

July 7, 2022 updated by: Burcin Becerik-Gerber, University of Southern California
This study aims at establishing a laboratory experiment that mimics office work stressors, examining the feasibility of automated stress detection, and identifying the most significant physiological and/or behavioral features that can be used to differentiate between positive stress (eustress) and negative stress (distress). Additionally, we will investigate if triggering the olfactory (exposing participants to pleasant smells) senses would help reduce stress.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The experiment is divided into 2 main phases:

The first phase is the eustress-distress data collection: In this phase, participants will complete three conditions:

  1. "No-stress": Participants will sit idle on their desks without performing any task. This is important to record a baseline of physiological signals that will allow us to compare the physiological responses in later stages.
  2. "Low-stress work": Participants will be asked to prepare a brief presentation about a familiar topic (e.g., favorite types of food, TV shows, academic work). A strict time limit will not be provided; instead, participants will be told that they have at least 30 minutes and up to 40 minutes if they need that amount of time to complete the presentation.
  3. "High-stress work": Participants will be required to prepare a presentation about an unfamiliar topic with a time limit of 30 minutes. The topic and the requirements will be carefully established to make the completion of the presentation achievable but at the same time to create a sense of time pressure, heavy workload, and unfamiliarity with the task. We will employ a concept similar to the Trier Social Stress Test, in which participants are required to develop and deliver a speech to a panel. This test has been employed in several studies as a means of inducing high-stress reactions. In our study, participants will be informed that a two-person judging committee will be scoring their work performance by watching through a Zoom shared screen. Participants will be told that their final score will be compared to all other study participants such that the highest scoring individuals will receive an award. The committee's "score" will be presented on the screen beginning at 100 and will be decreased and increased in a standardized manner across all participants. Changes in the score will appear at uneven intervals such that the participants do not recognize a pattern but associate the scoring with the judging committee noticing some sort of work flaw or issue. A countdown clock with time remaining will be presented on the screen, recorded office noise (e.g., printers, distant chatting, computers) will be played in the background, and temperature will be increased outside the comfort range. In addition, participants will be subject to interruptions including pop-up messages, calls or emails every 5 minutes to ask about progress.

During the three conditions (idle, low stress, high stress) participants will be asked 5 questions every 5 minutes:

  1. In the last five minutes, to what extent did you consider the work you are performing as an opportunity or challenge?
  2. In the last five minutes, to what extent did you consider the work you are performing as a source of pressure?
  3. Over the last five minutes, how would you rate your productivity?
  4. Over the last five minutes, how would you rate your mood?
  5. Over the last five minutes, how would you rate your stress level?

The second phase is meant to investigate if triggering the olfactory (exposing participants to pleasant smells) senses would help reduce stress.

For that, participants will be given a task that an office worker usually conducts in their everyday work (e.g., typing a paragraph in a word document, organizing a spreadsheet) for 20 minutes. During the 20 minutes, participants will get exposed to one of the following three conditions:

  1. Control group - 20 participants: No exposure to smells or change in office light settings.
  2. Olfactory group 1 - 20 participants: No change in office light settings, but participants in this condition will be exposed to the smell of natural wood scent continuously. A diffuser with essential oils will be turned on during that time to deliver the smell.
  3. Olfactory group 2 - 20 participants: No change in office light settings, but participants in this condition will be exposed to the smell of Bergamot scent continuously. A diffuser with essential oils will be turned on during that time to deliver the smell.

Following this, participants will be asked to rate their anxiety/stress levels using the state anxiety trait survey and how they perceived the exposure to the scents.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
50

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90089
        • University of Southern California

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Participants will be older than 18.
  2. Participants should be proficient at speaking and writing in English.
  3. Qualified participants should have a normal or corrected-to-normal vision, and a normal sense of smell.

Exclusion Criteria:

  1. Participants will be screened to make sure that they don't have any physical or psychological-related problems that make them sensitive to stress-inducing tasks.
  2. Participants who are taking any medication to regulate their blood pressure will not be allowed to participate in the study as these medications might affect the quality of the blood volume pulse-related data.
  3. Pregnant women are not allowed to participate in this study.
  4. Participants using prescription medication, diagnosed with color blindness, rhinitis, or hay fever, or have allergic reactions to essential oils ( e.g., contact dermatitis, allergic rhinitis) will not be allowed to participate in this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
No Intervention: Control
No exposure to smells.
Experimental: Olfactory Condition - 1
Participants in this condition will be exposed to the smell of natural wood scent continuously. A diffuser with essential oils will be turned on during that time to deliver the smell.
Other: Natural wood scent
Wood notes tend to be rich and warm, often forming the base of a scent due to their aromatic weight.
Experimental: Olfactory Condition - 2
Participants in this condition will be exposed to the smell of Bergamot scent continuously. A diffuser with essential oils will be turned on during that time to deliver the smell.
Other: Bergamot scent
The scent of bergamot is fruity and citrusy, with floral hints and spice notes.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Heart rate
Time Frame: Throughout study participation, up to 120 minutes
Heart rate will be collected through a sensor attached to the participant's chest at a collection rate of 1 heart rate reading per second. The average heart rate will be examined across study conditions.
Throughout study participation, up to 120 minutes
Electrodermal activity
Time Frame: Throughout study participation, up to 120 minutes
Electrodermal activity will be collected through a sensor placed on the wrist similar to a watch, with data collection at a rate of 4 readings per second. The average electrodermal activity will be examined across study conditions.
Throughout study participation, up to 120 minutes
Blink rate
Time Frame: Throughout study participation, up to 120 minutes
A facial detection algorithm will be used to detect the blinking rate of the participant from a camera that collects 10 frames per second. The average blink rate will be examined across study conditions.
Throughout study participation, up to 120 minutes
Gaze angle
Time Frame: Throughout study participation, up to 120 minutes
A facial detection algorithm will be used to detect the gaze angle direction of the participant from a camera that collects 10 frames per second. The durations of gaze angles will be examined across study conditions.
Throughout study participation, up to 120 minutes

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Mouse clicks
Time Frame: Throughout study participation, up to 120 minutes
The number of mouse clicks will be recorded using a logger software installed on the computer. The frequency of mouse clicks will be examined across study conditions.
Throughout study participation, up to 120 minutes
Keyboard keystrokes
Time Frame: Throughout study participation, up to 120 minutes
The number of keystrokes will be recorded using a logger software installed on the computer. The frequency of keystrokes will be examined across study conditions.
Throughout study participation, up to 120 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Southern California

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Southern California NIOSH Education and Research Center

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Burcin Becerik-Gerber, PhD, University of Southern California

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 5, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 5, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 20, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 4, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 16, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 8, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 7, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • UP-21-00484

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress

Clinical Trials on Natural wood scent

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings